Drug Combo's Long-Term safety under scrutiny in blood disease patients

NCT ID NCT02386800

Ongoing Disease control Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jul 02, 2026 · Updated 3 times

Summary

This study follows patients who have already been taking ruxolitinib alone or with panobinostat in earlier trials and are still benefiting. Researchers will track side effects over time to see how safe these drugs are for long-term use. About 296 participants with conditions like myelofibrosis, polycythemia vera, or graft-versus-host disease are being monitored.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: ruxolitinib and panobinostat
What this could lead to: If successful, this study could confirm that these drugs are safe for long-term use in conditions like myelofibrosis and graft-versus-host disease.
What could go wrong: This is an open-label, long-term safety study, not designed to prove effectiveness. Side effects may still emerge over time, and results may not apply to new patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acquired polycythemia vera acute myeloid leukemia Bronchiolitis Obliterans Syndrome graft versus host disease primary myelofibrosis thalassemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ACUTE MYELOID LEUKEMIA GRAFT-VERSUS-HOST DISEASE POLYCYTHEMIA VERA PRIMARY MYELOFIBROSIS THALASSEMIA

Contacts and locations

Locations

Novartis Investigative Site

Darlinghurst, New South Wales, 2010, Australia
Novartis Investigative Site

Herston, Queensland, 4029, Australia
Novartis Investigative Site

Wooloongabba, Queensland, 4102, Australia
Novartis Investigative Site

Bedford Park, South Australia, 5041, Australia
Novartis Investigative Site

Box Hill, Victoria, 3128, Australia
Novartis Investigative Site

Clayton, Victoria, 3168, Australia
Novartis Investigative Site

Franston, Victoria, 3199, Australia
Novartis Investigative Site

Perth, Western Australia, 6000, Australia
Novartis Investigative Site

St Leonards, 2065, Australia
Novartis Investigative Site

Leuven, Vlaams Brabant, 3000, Belgium
Novartis Investigative Site

Antwerp, 2020, Belgium
Novartis Investigative Site

Bruges, 8000, Belgium
Novartis Investigative Site

Liège, 4000, Belgium
Novartis Investigative Site

Pleven, 5800, Bulgaria
Novartis Investigative Site

Plovdiv, 4002, Bulgaria
Novartis Investigative Site

Sofia, 1431, Bulgaria
Novartis Investigative Site

Toronto, Ontario, M5G 1X8, Canada
Novartis Investigative Site

Santiago, RM, 7500922, Chile
Novartis Investigative Site

Viña del Mar, Valparaiso, 2540364, Chile
Novartis Investigative Site

Santiago, 8420383, Chile
Novartis Investigative Site

Hangzhou, Zhejiang, 310003, China
Novartis Investigative Site

Beijing, 100730, China
Novartis Investigative Site

Paris, 75475, France
Novartis Investigative Site

Dresden, Saxony, 01307, Germany
Novartis Investigative Site

Jena, Thuringia, 07740, Germany
Novartis Investigative Site

Aachen, 52074, Germany
Novartis Investigative Site

Dresden, 01307, Germany
Novartis Investigative Site

Hamburg, 20246, Germany
Novartis Investigative Site

Magdeburg, 39120, Germany
Novartis Investigative Site

Mainz, 55131, Germany
Novartis Investigative Site

Ulm, 89081, Germany
Novartis Investigative Site

Athens, 115 27, Greece
Novartis Investigative Site

Pátrai, 265 04, Greece
Novartis Investigative Site

Debrecen, Hajdu Bihar Megye, 4032, Hungary
Novartis Investigative Site

Budapest, H-1097, Hungary
Novartis Investigative Site

Kaposvár, 7400, Hungary
Novartis Investigative Site

Kecskemét, 6001, Hungary
Novartis Investigative Site

Szeged, H 6725, Hungary
Novartis Investigative Site

Szombathely, H-9700, Hungary
Novartis Investigative Site

Pune, Maharashtra, 411004, India
Novartis Investigative Site

Afula, 1834111, Israel
Novartis Investigative Site

Jerusalem, 9112001, Israel
Novartis Investigative Site

Ancona, AN, 60020, Italy
Novartis Investigative Site

Bari, BA, 70124, Italy
Novartis Investigative Site

Bologna, BO, 40138, Italy
Novartis Investigative Site

Brescia, BS, 25123, Italy
Novartis Investigative Site

San Giovanni Rotondo, FG, 71013, Italy
Novartis Investigative Site

Florence, FI, 50134, Italy
Novartis Investigative Site

Milan, MI, 20122, Italy
Novartis Investigative Site

Milan, MI, 20132, Italy
Novartis Investigative Site

Milan, MI, 20162, Italy
Novartis Investigative Site

Rozzano, MI, 20089, Italy
Novartis Investigative Site

Palermo, PA, 90146, Italy
Novartis Investigative Site

Pavia, PV, 27100, Italy
Novartis Investigative Site

Reggio Calabria, RC, 89124, Italy
Novartis Investigative Site

Roma, RM, 00161, Italy
Novartis Investigative Site

Orbassano, TO, 10043, Italy
Novartis Investigative Site

Varese, VA, 21100, Italy
Novartis Investigative Site

Naples, 80138, Italy
Novartis Investigative Site

Nagoya, Aichi-ken, 453-8511, Japan
Novartis Investigative Site

Nagoya, Aichi-ken, 4668560, Japan
Novartis Investigative Site

Sapporo, Hokkaido, 060-8648, Japan
Novartis Investigative Site

Isehara, Kanagawa, 259-1193, Japan
Novartis Investigative Site

Suita, Osaka, 565-0871, Japan
Novartis Investigative Site

Bunkyo Ku, Tokyo, 1138677, Japan
Novartis Investigative Site

Fukuoka, 8128582, Japan
Novartis Investigative Site

Osaka, 5458586, Japan
Novartis Investigative Site

Beirut, 113-0236, Lebanon
Novartis Investigative Site

Monterrey, Nuevo León, 64718, Mexico
Novartis Investigative Site

Gliwice, Silesian Voivodeship, 44-101, Poland
Novartis Investigative Site

Wroclaw, 50 367, Poland
Novartis Investigative Site

Lisbon, 1099-023, Portugal
Novartis Investigative Site

Lisbon, 1649-035, Portugal
Novartis Investigative Site

Moscow, 125167, Russia
Novartis Investigative Site

Moscow, 125284, Russia
Novartis Investigative Site

Moscow, 129110, Russia
Novartis Investigative Site

Petrozavodsk, 185019, Russia
Novartis Investigative Site

Saint Petersburg, 197022, Russia
Novartis Investigative Site

Pretoria, Gauteng, 0181, South Africa
Novartis Investigative Site

Soweto, Gauteng, 2013, South Africa
Novartis Investigative Site

Cape Town, Western, 7800, South Africa
Novartis Investigative Site

Pretoria, 0027, South Africa
Novartis Investigative Site

Seoul, 03080, South Korea
Novartis Investigative Site

Seoul, 03722, South Korea
Novartis Investigative Site

Seoul, 06591, South Korea
Novartis Investigative Site

Barcelona, Catalonia, 08003, Spain
Novartis Investigative Site

Pamplona, Navarre, 31008, Spain
Novartis Investigative Site

Salamanca, 37007, Spain
Novartis Investigative Site

Huddinge, SE-14186, Sweden
Novartis Investigative Site

Luleå, SE 971 80, Sweden
Novartis Investigative Site

Lund, SE-221 85, Sweden
Novartis Investigative Site

Uddevalla, 451 80, Sweden
Novartis Investigative Site

Bangkok, 10700, Thailand
Novartis Investigative Site

Istanbul, Fatih, 34093, Turkey (Türkiye)
Novartis Investigative Site

Kayseri, Melikgazi, 38039, Turkey (Türkiye)
Novartis Investigative Site

Ankara, Sihhiye-Altindag, 06230, Turkey (Türkiye)
Novartis Investigative Site

Izmir, 35100, Turkey (Türkiye)

More trials for these conditions

Other studies related to the condition(s) this trial covers.